InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region

B45. COPD: TREATMENT Pub Date : 2019-05-01 DOI:10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3309

R. Wise, G. Criner, M. Dransfield, M. Han, C. E. Jones, S. Lettis, F. Martinez, S. Pascoe, H. Quasny, David A. Lipson

引用次数: 0

查看原文本刊更多论文

告知慢性阻塞性肺病治疗途径(IMPACT研究)-单吸入器三联治疗(糠酸氟替卡松/乌莫列地铵/维兰特罗)与糠酸氟替卡松/维兰特罗和乌莫列地铵/维兰特罗治疗慢性阻塞性肺病患者:基于北美地区分析的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

B45. COPD: TREATMENT

自引率

0.00%

发文量